Stereotaxis, Inc. (STXS) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended September 30, 2025. Stereotaxis, Inc. designs and markets robotic magnetic navigation systems and interventional devices, primarily for cardiac ablation procedures. The company operates as a non-accelerated filer and smaller reporting company. As of October 31, 2025, there were 93,324,763 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Total Revenue | $7.46 million | $9.20 million | $23.74 million | $20.58 million |
| Gross Margin | 55% | 45% | 54% | 55% |
| Operating Loss | ($6.56 million) | ($6.35 million) | ($16.46 million) | ($17.11 million) |
| Net Loss | ($6.46 million) | ($6.19 million) | ($16.11 million) | ($16.53 million) |
| Cash & Equivalents | $10.51 million (as of Sept 30, 2025) | |||
| Working Capital | $6.29 million (as of Sept 30, 2025) | |||
| Debt | None |
Material Changes vs. Prior Period
- Revenue Mix Shift: Q3 2025 total revenue decreased 19% year-over-year, driven by a 58% decline in system sales ($1.86M vs $4.39M). However, recurring revenue from disposables, service, and accessories increased 17% ($5.60M vs $4.81M), reflecting the full-quarter impact of the Access Point Technologies (APT) acquisition.
- Margin Expansion: Gross margin improved to 55% in Q3 2025 from 45% in Q3 2024, attributed to a favorable shift in product mix toward higher-margin disposables and services.
- Expense Management: Operating expenses remained relatively flat quarter-over-quarter. General and Administrative (G&A) expenses increased slightly due to contingent consideration revaluation related to the APT acquisition, partially offset by lower administrative costs.
- Capital Raise: In July 2025, the company completed a registered direct offering, raising approximately $7.8 million in net proceeds. An additional $4.0 million in proceeds is expected from a milestone closing in November 2025.
Outlook, Risks, and Management Commentary
- Regulatory Milestones: The company received FDA 510(k) clearance for the MAGiC Sweep catheter in July 2025 and CE marking for the Synchrony system in October 2025. The GenesisX RMN System received FDA clearance in Q4 2025 (per filing text).
- Tariff and Trade Risks: Management highlights significant exposure to global tariff fluctuations. While USMCA-qualified sub-assemblies from Mexico are exempt, new baseline tariffs on non-USMCA imports and potential tariffs on European medical devices could increase costs or delay U.S. product launches. Reciprocal tariffs with China remain suspended through November 2026.
- Liquidity: The company maintains a cash balance of $10.5 million and has established a $50 million "at-the-market" (ATM) equity offering program. Management believes current resources are sufficient to fund operations through 2025 but notes the potential need for future dilutive financing.
- Acquisition Integration: The company continues to integrate APT, which provides in-house catheter manufacturing. This integration introduces complexity and potential supply chain risks but is expected to drive future innovation.
Investor Verification Checklist
- System Sales Volatility: Verify the pipeline for capital system sales, as Q3 2025 saw a significant drop compared to the prior year.
- Contingent Consideration: Monitor the fair value adjustments of the APT earn-out liability, which impacted G&A expenses by $1.81 million in the first nine months of 2025.
- Tariff Impact: Assess the potential cost impact of the 10% baseline tariff on non-USMCA imports and the status of negotiations regarding EU medical device tariffs.
- Equity Dilution: Track the utilization of the new $50M ATM facility and the timing of the additional $4M closing from the July 2025 offering.
- Regulatory Approvals: Confirm the commercialization timeline for the Synchrony system and MAGiC catheter in the U.S. market following recent clearances.